Search the Newsreel

Inhibrx Biosciences (INBX) Slides 8% to $89.22: Support at $84.76 Becomes Key Test - NHNL Divergence

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G

American Century ETF Trust and its affiliates, including American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research, have reported passive ownership stakes in Emergent BioSolutions Inc. (EBS) common stock via a Schedule 13G filing. The ETF Trust …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake

Anixa Biosciences (ANIX) Slips 0.63% to $3.18 as Shares Consolidate Between Key Support and Resistance - Pre-Earnings Momentum

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

Forte Biosciences (FBRX) Holds Near $76.86 as Key Resistance at $80.70 Caps Near-Term Move - Ichimoku TK Cross

Winking Studios Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8

Citi has reiterated its Buy rating for Caribou Biosciences (CRBU.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Twist Bioscience (NASDAQ:TWST) Trading Down 4.3% - Here's What Happened

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and …

Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss

Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …

Armistice Capital (RPID) discloses 3.33M-share position in Rapid Micro Biosystems

Armistice Capital, LLC and Steven Boyd have disclosed a 7.29% stake in Rapid Micro Biosystems, Inc. (RPID), amounting to 3,328,000 shares of Class A common stock. All voting and dispositive power over these shares is shared, with Armistice Capital acting as the investment manager …

TuHURA Biosciences, Inc. - Common Stock (HURA) Stock Price, News, Quote & History

This article provides a comprehensive overview of TuHURA Biosciences, Inc. (HURA) stock, including its current price, market data, and recent news. It highlights the company's focus on advancing biotechnology solutions, particularly in developing therapies and diagnostic tools. The news section features updates on their …

Armistice Capital (RKDA holder) discloses 9.99% beneficial stake in Arcadia Biosciences

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Arcadia Biosciences, Inc., totaling 267,392 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, exercising shared voting and dispositive power. …

Form 8K Skye Bioscience Inc For: 14 August By Investing.com

This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …

GUFICBIO: Q1 FY27 saw strong profit growth and a major international expansion into the Philippines

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase …

TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside

Analysts have cut the 12-month average price target for Caribou Biosciences, Inc. stock from $12 to $11.86, with individual forecasts ranging from $4 to $32 per share. Despite the slight reduction in the average target, this still implies a significant 636% potential upside based …

Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure

Alamar Biosciences (ALMR) stock surged 30.7% after its first post-IPO quarter, despite reporting a net loss of US$13.2m. The company achieved US$29.4m in revenue and a record 60% gross margin, driven by strong demand for consumables and instruments. While bulls highlight top-line growth and …

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line

Skye Bioscience is set to acquire Redx through a UK court-sanctioned scheme of arrangement, backed by a significant financing package. The deal includes a $67.9 million equity financing (potentially rising to $72.9 million), a $22.0 million equity line, and a $5.0 million warrant with …

Navios Maritime Partners (NMM) Q1 2024 Earnings Report - Results, Call & Slides

Navios Maritime Partners (NMM) reported strong Q1 2024 earnings, beating analyst expectations with an actual EPS of $2.32 against a consensus of $2.01, and revenue of $318.56 million against an expected $283.59 million. This marks a 2.92% year-over-year revenue growth. The company has also …

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, forming a combined company named Fibrx Therapeutics, which will focus on developing novel small molecule medicines for fibrotic diseases. This merger is supported by approximately $125 million in financings, including a PIPE financing …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G/A for Artelo Biosciences (ARTL), reporting that they no longer beneficially own any common stock in the company. As of June 30, 2026, their ownership stake is 0 shares, representing 0.0% of the …

Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Sagimet Biosciences (NASDAQ:SGMT) Given New $29.00 Price Target at Citizens Jmp

Assembly Biosciences, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ASMB | US0453962070

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences (RKDA) announced its second quarter and first half 2026 financial results, highlighting a significant reduction in cash used in operating activities and a strong cash balance. The company reported flat sales for Q2 2026 due to inventory and shipping issues, which have …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …